Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer
Clinical trial NCT02351739 · COMPLETED
Trial details
- NCT number
- NCT02351739
- Sponsor
- Acerta Pharma BV
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-04-01
- Primary completion
- 2018-02-01
- Enrollment
- 78
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.